Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

Study provides prospective, clinically-validated performance data at challenging low fetal fraction levels, raising industry standard

Reduces no-call rate to 0.5%, enabling results for more patients and closing a key competitive gap

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company’s novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by clinically-validated performance data in samples with low fetal fraction, enabling a no-call rate of 0.5%.

Fetal fraction refers to the proportion of placental DNA circulating in a pregnant patient’s blood sample. Low fetal fraction can make it more difficult to accurately detect chromosomal abnormalities in prenatal screening. Patients with low fetal fraction are associated with a significantly increased risk of aneuploidy.